AroCell: Improved measurement of Thymidine Kinase 1 within the normal range due to improved composition of the zero calibrator.
August 12 2016 - 10:58AM
Thymidine Kinase 1 (TK1) is a key enzyme in DNA
synthesis and it is produced by and released into the blood from
proliferating cells, especially tumor cells. It is a well-studied
biomarker for studying tumor growth.
TK1 levels in the blood of healthy subjects are
very low, requiring sensitive assays. When developing such assays,
establishing the zero calibrator, or blank, value is a key point as
it determines the limit of sensitivity.
ArOCell has redesigned the preparation of the zero
Calibrator in its TK 210 ELISA kit, replacing the current human
serum based material with a proprietary buffer-based Calibrator.
The benefit of the change is better discrimination of TK1 values in
samples with low-normal values. The performance of the Arocell TK
210 ELISA with the new zero calibrator in healthy subjects will be
presented by Dr. Kiran Kumar Jagarlamudi, clinical research manager
at AroCell at the annual meeting of the International Society of
Oncology and Biomarkers (ISOBM) in Chicago next month, September
4th.
We are pleased that we have improved the TK 210
ELISA, but one should keep in mind that establishment of the value
of this increased sensitivity and discrimination will require
further studies including material from subjects with known
pathologies says Jan Stålemark, CEO at AroCell.
For additional
information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706 926206
info@arocell.com
www.arocell.com
About AroCell
AroCell AB (publ) is a Swedish company
that develops standardized modern blood tests to support the
prognosis and follow up of cancer patients. AroCell's new
technology is based on patented methods to measure TK1 protein
levels, which provide valuable information about the speed of cell
turnover. A tumor has high cell turnover (speed of cell division
and cell death) and as a result TK1 can be detected in the blood
with a simple laboratory test, called TK 210 ELISA. The test
provides valuable clinical information for prognosis and
optimization of treatment strategy. The test may also be used for
monitoring disease relapse. For more information, please see
www.arocell.com. This information is information
that AroCell is obliged to make public pursuant to the EU Market
Abuse Regulation. The information was submitted for publication,
through Jan Stålemark, at 16:58 CET on 12 August 2016. Redeye is
AroCell:s Certified Adviser.
The News in PDF
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: AroCell AB via Globenewswire
HUG#2035079
Archrock (NYSE:AROC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Archrock (NYSE:AROC)
Historical Stock Chart
From Sep 2023 to Sep 2024